Abstract:

Objective To determine the matrix metalloproteinase-13(MMP-13) and transform growth factor beta 1 (TGF-β1) in patients with chronic liver disease, and to analyze the correlation and clinical significance. Methods A total of 50 chronic hepatitis patients, 50 cirrhosis patients, 60 liver carcinoma patients and 50 healthy subjects (healthy control group) were enrolled and determined for MMP-13 and TGF-β1 by enzyme-linked immunosorbent assay (ELISA). Results The MMP-13 in the chronic hepatitis patients, cirrhosis patients, liver carcinoma patients and healthy controls were 287.05±29.80, 328.04±62.03, 329.02±70.04 and (279.03±32.80) ng/L. The TGF-β1 in the chronic hepatitis patients, cirrhosis patients, liver carcinoma patients and healthy controls were 0.99±0.11, 0.96±0.12, 2.22±1.08 and (0.65±0.09) μg/L. The expressions of MMP-13 and TGF-β1 in patients with chronic hepatitis, cirrhosis and liver carcinoma were higher than those in healthy controls. The serum MMP-13 in cirrhosis and liver carcinoma patients were much higher than those in chronic hepatitis patients (P<0.01). The TGF-β1 in liver carcinoma patients was higher than those in cirrhosis and chronic hepatitis patients (P<0.01). In comparison to healthy controls, the TGF-β1 in the cirrhosis and chronic hepatitis patients had no statistical significance (P>0.05). Conclusions In the development of chronic liver diseases, the MMP-13 and TGF-β1 express excessively. The dynamic analysis of their levels may be helpful to the diagnosis and monitoring of chronic disease.

Key words: Matrix metalloproteinase-13, Transform growth factor beta 1, Chronic hepatitis, Cirrhosis, Liver carcinoma